In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model

Journal of Immunology

Volumn 161, Issue 3, 1998, Pages 1454-1461

  De Jonge, Jan ^a   Heirman, Carlo ^a   De Veerman, Marijke ^a   Van Meirvenne, Sonja ^a   Moser, Muriel ^b   Leo, Oberdan ^b   Thielemans, Kris ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; RECOMBINANT INTERLEUKIN 2; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; EXPRESSION VECTOR; GENETIC HETEROGENEITY; IMMUNOTHERAPY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; ENTEROTOXINS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; INJECTIONS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0032146168     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Brissinck, J., C. Demanet, O. Leo, and K. Thielemans. 1992. Bispecific antibody therapy. Drugs Future 17:1003.
2. Holliger, P., and G. Winter. 1993. Engineering bispecific antibodies. Curr. Opin. Biotechnol. 4:446.
3. Renner, C., and M. Pfreundschuh. 1995. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev. 145:179.
4. Brissinck, J., C. Demanet, M. Moser, O. Leo, and K. Thielemans. 1991. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J. Immunol. 147:4019.
5. Demanet, C., J. Brissinck, M. Van Mechelen, O. Leo, and K. Thielemans. 1991. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3). J. Immunol. 147:1091.
6. Mezzanzanica, D., S. Canevari, and M. I. Colnaghi. 1991. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int. J. Clin. Lab. Res. 21:159.
7. Lamers, C., J. Gratama, S. Wamaar, G. Stoter, and R. Bolhuis. 1995. Inhibition of bispecific mAb-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int. J. Cancer 60:450.
8. 1 fragments. Science 229:81.
9. Milstein, C., and A. C. Cuello. 1983. Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537.
10. George, A. J. T., J. A. Titus, C. R. Jost, I. Kurucz, P. Perez, S. M. Andrew, P. J. Nicholts, J. S. Huston, and D. M. Segal. 1994. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J. Immunol. 152:1802.
11. Gruber, M., B. A. Schodin, E. R. Wilson, and D. M. Kranz. 1994. Efficient tumor cell lysis mediated by a bispecific single-chain antibody expressed in Escherichia coli. J. Immunol. 152:5368.
12. Mallender, W. D., and E. W. Voss Jr. 1994. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J. Biol Chem. 269:199.
13. De Jonge, J., J. Brissinck, C. Heirman, C. Demanet, O. Leo, M. Moser, and K. Thielemans. 1995. Production and characterization of bispecific single-chain antibody fragments. Mol. Immunol. 32:1405.
14. Kurucz, I., J. Titus, C. Jost, C. Jacobus, and D. Segal. 1995. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J. Immunol. 154:4576.
15. Mack, M., G. Riethmuller, and P. Kufer. 1995. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 92:7021.
16. Holliger, P., T. Prospero, and G. Winter. 1993. 'Diabodies': small bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90:6444.
17. Yokota T., D. E. Milenic, M. Whitlow, and J. Schlom. 1992. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:3402.
18. Demanet, C., J. Brissinck, J. De Jonge, and K. Thielemans. 1996. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced co-stimulation. Blood 87:4390.
19. Kuwahara, M., M. Kuroki, F. Arakawa, T. Senba, Y. Matsuoka, T. Hideshima, Y. Yamashita, and H. Kanda. 1996. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res. 16:2661.
20. Luiten, R., L. Coney, G. Fleuren, S. Warnaar, and S. Litvinov. 1996. Generation of chimeric bispecific G250/anti-CD3 mAb, a tool to combat renal cell carcinoma. Br. J. Cancer 74:735.
21. Laroche, Y., M. Demaeyer, J. Stassen, Y. Gansemans, E. Demarsin, G. Matthyssens, D. Collen, and P. Holvoet. 1991. Characterization of a recombinant single chain molecule comprising the variable domains of a mAb specific for human fibrin fragment D-dimer. J. Biol Chem. 266:16343.
22. Kretzschmar, T., L. Aoustin, O. Zingel, M. Marangi, B. Vonach, H. Towbin, and M. Geiser. 1996. High level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. J. Immunol. Methods 195:93.
23. H orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions. J. Biochem. 118:825.
24. Holliger, P., J. Brissinck, R. Williams, K. Thielemans, and G. Winter. 1996. Specific killing of lymphoma cells by cytotoxic T cells mediated by a bispecific diabody. Protein Eng. 9:299.
25. McGuinness, B., G. Walter, K. Fitzgerald, P. Schuler, W. Mahoney, A. Duncan, and H. Hoogenboom. 1996. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments. Nat Biotechnol. 14:1149.
26. Weiner, G. J., S. A. Kostelny, J. R. Hillstrom, M. S. Cole, B. K. Link, S. L. Wang, and J. Y. Tso. 1994. The role of T cell activation in anti-CD3 × anti-tumor bispecific antibody therapy. J. Immunol. 152:2385.
27. Chapoval, A. I., H. Nelson, C. Thibault, C. Penna, and P. Dean. 1995. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application. J. Hematother. 4:571.
28. Hendrzak, J., and M. Brunda. I995. Interieukin-12: biologic activity, therapeutic utility, and role in disease. Lab. Invest. 72:619.
29. Bertagnolli, M., B. Lin, D. Young, and H. Herrmann. 1992. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J. Immunol. 149:3778.
30. Zen, H., S. Hurd, W. Storkus, and T. Lotze. 1993. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunother. 14:155.
31. Cesano, A., S. Visonneau, S. Clark, and D. Santoli. 1993. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J. Immunol. 151:2943.
32. Sahin, U., S. Kraft-Bauer, S. Ohnesorge, M. Pfreundschuh, and C. Renner. 1996. Interleukin-12 increases bispecific antibody-mediated NK cell cytotoxicity against human tumors. Cancer Immunol. Immunother. 42:9.
33. Uhr, J. W., R. H. Scheuermann, N. E. Street, and E. S. Vitetta. 1997. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med. 3:505.
34. Slavin, S., and S. Strober. 1978. Spontaneous murine B cell leukemia. Nature 272:624.
35. Kim, K. J., C. Kanellopoulos-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofski. 1979. Establishment and characterization of BALB/c Iymphoma lines with B cell properties. J. Immunol. 122:549.
36. Stephens, P. E., and M. I. Cockett. 1989. The construction of a highly efficient and versatile set of mammalian expression vectors. Nucleic Acids Res. 17:7110.
37. Keen, N., and S. Tamaki. 1986. Structure of two pectate lyase genes from Erwinia chrysanthemi EC16 and their high-level expression in Escherichia coli. J. Bacteriol. 168:595.
38. Ausubel, F. M., R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smith, and K. Struhl. 1987. Current Protocols in Molecular Biology. J. Wiley & Sons, Inc., New York.
39. Donckier, V., V. Flamand, F. Desalle, M.-L. Vanderhaegen, M. De Veerman, K. Thielemans, D. Abramowicz, and M. Goldman. 1998. Interleukin-12 prevents neonatal induction of transplantation tolerance in mice. Eur. J. Immunol., In press.
40. Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter. 1991. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581.
41. Renner, C., G. Held, S. Ohnesorge, S. Bauer, K. Gerlach, J. P. Pfitzenmeier, and M. Pfreundschuh. 1997. Role of perform, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol. Immunother. 44:70.
42. Renner, C., W. Jung, U. Sahin, R. Denfeld, C. Pohl, L. Trumper, F. Hartmann, V. Diehl, R. van Lier, and M. Pfreundschuh. 1994. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833.
43. Demanet, C., J. Brissinck, J. De Jonge, and K. Thielemans. 1995. In vivo studies using bispecific antibodies (anti-CD3 × anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. J. Hematother. 4:363.
44. Belfrage, H., M. Dohlsten, G. Hedlund, and T. Kalland. 1995. Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo. Cancer Immunol. Immunother. 41:87.
45. Zou, J., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. Herrmann, S. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
46. Pugatsch, T., L. Weiss, and S. Slavin. 1993. Minimal residual disease in murine B cell leukemia (BCL1) detected by PCR. Leukemia Res. 17:999.
47. Vitetta, E. S., T. F. Tucker, E. Racila, Y. Huang, R. Marches, N. Lane, R. H. Scheuermann, N. E. Street, T. Watanabe, and J. W. Uhr. 1997. Tumor dormancy and cell signaling: regrowth of the BCL1 tumor after dormancy is established. Blood 89:4425.
48. Meeker, T., J. Lowder, M. L. Cleary, S. Stewart, R. Warnke, J. Sklar, and R. Levy. 1985. Emergence of idiotype variants during treatment of B cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312:1658.
49. Carroll, W., J. Lowder, R. Streifer, R. Warnke, S. Levy, and R. Levy. 1986. Idiotype variant cell populations in patients with B cell lymphoma. J. Exp. Med. 164:1566.
50. De Gast, G. C., A. A. Van-Houten, I. A. Haagen, S. Klein, R. A. De Weger, A. Van-Dijk, J. Phillips, M. Clark, and B. J. Bast. 1995. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J. Hematother. 4:433.
51. Kurucz, I., J. A. Titus, C. R. Jost, and D. M. Segal. 1995. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies. Mol. Immunol. 32:1443.